Pulmonary Arterial Hypertension (PAH)Lungs and breathingDrugPhase 1
What this study is
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
What's being tested
- Artesunate
Intervention · DRUG
Participants will receive artesunate capsules. Participants will receive artesunate capsules TID in a dose escalation manner (60 mg, 120 mg, 180 mg total daily).
Study details
- Official title
- Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
- Sponsor
- Joseph C. Wu
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Enrolling
- 15 people
- Starts
- 2026-04-01
- Est. completion
- 2029-01-01
- Design
- Open-label, single group, Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 60 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Adults aged 18 to 75 years.
- WHO functional class I, II/III despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids when appropriate.
You can't join if
- Participants who meet any of the following criteria will be excluded from the study.
- Participants with serious concomitant morbidity per investigator assessment.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openStanford University
Stanford, California, United States
- Roham Zamanian, MD · Contact(650) 725-7061roham.zamanian@stanford.edu
Recruiting
Study team
Sponsor
Joseph C. Wu
Study ID 80578
Study director
Roham Zamanian, MD
Stanford University
Have questions? The record lists no central contact. Use Consider me and the site team can reach you, or find them through ClinicalTrials.gov ↗.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.